<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925779</url>
  </required_header>
  <id_info>
    <org_study_id>2019/3/15/9</org_study_id>
    <nct_id>NCT03925779</nct_id>
  </id_info>
  <brief_title>Conscious Sedation for Outpatient Colonoscopy</brief_title>
  <official_title>Dexmedetomidine Versus Propofol-Remifentanil Conscious Sedation for Outpatient Colonoscopy: A Prospective Randomized Double-blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although colonoscopy is a mildly painful procedure, the pain and the procedure itself are
      distressful for most patients. This raises the attention for using different sedation
      regimens aiming at maintaining optimal sedation level with maintained airway and stable
      haemodynamics all through the procedure. The present study was scheduled to investigate the
      sedative efficacy of dexmedetomedine versus propofol-remifentanil for outpatient colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty patients undergoing outpatient colonoscopy will be randomized into two equal groups.
      In Dexmedetomidine (DEX) group the patients will be administered a loading dose of i.v.
      dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h,
      titrated according to the sedation score, till the end of the procedure. In the PR group,
      propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance
      infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute
      then and 0.01-0.1 μg kg/min. If the patient complained of pain or discomfort, the infusion
      rates of dexmedetomidine (DEX group) or propofol-remifentanil (P-R group) will be increased.
      If the higher limit of the dose range of the study drugs reached, additional fentanyl 0.5
      μg/kg i.v. boluses will be administered. Rescue medication consisting of propofol boluses of
      0.5 mg/kg i.v. will be given if the previous protocol failed. Sedation score,haemodynamics,
      end-tidal carbon dioxide, oxygen saturation, total fentanyl, propofol bolus doses, patient
      and colonoscopist satisfaction and side effects will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>A blinded investigator that was not involved in the anaesthetic management of the patients, collected the intra-operative and postoperative data. The patients and colonoscopist were blinded to group allocation. For blinding purposes, two drug infusion pumps were used in every patient where the infusion pumps and i.v. connection lines were concealed to avoid identification.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation</measure>
    <time_frame>Perioperative</time_frame>
    <description>Degree of sedation by Ramsay sedation score from 1 inadequate sedation to 6 excessive sedation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>Perioperative</time_frame>
    <description>Mean arterial blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Perioperative</time_frame>
    <description>Heart rate in beats/minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Perioperative</time_frame>
    <description>Arterial oxygen saturation as a percentage of the total haemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>Perioperative</time_frame>
    <description>Number of patients with hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>Perioperative</time_frame>
    <description>Number of patients with bradycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia</measure>
    <time_frame>Perioperative</time_frame>
    <description>Measured by visual analogue scale [from 0 &quot;no pain&quot; to 10 &quot;worst imaginable pain&quot;]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>(Dexmedetomidine)Dex group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol-Remifentanil (P-R) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine sedation</description>
    <arm_group_label>(Dexmedetomidine)Dex group</arm_group_label>
    <other_name>dexmedetomidine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>propofol sedation</description>
    <arm_group_label>Propofol-Remifentanil (P-R) group</arm_group_label>
    <other_name>propofol infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil sedation</description>
    <arm_group_label>Propofol-Remifentanil (P-R) group</arm_group_label>
    <other_name>Remifentanil infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I or II physical status

          -  18-65 years

          -  Scheduled for elective colonoscopy

        Exclusion Criteria:

          -  History of allergy to any of the study drugs

          -  Alcohol or drug abuse.

          -  Second and third-degree heart block.

          -  Morbid obesity.

          -  Pregnant and lactating women.

          -  Psychiatric disorders.

          -  Severe cardiac, respiratory, renal, and liver diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abd-Elazeem A Elbakry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <state>Shebin El-kom</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Abd-Elazeem Abd-Elhameed Elbakry</investigator_full_name>
    <investigator_title>Associate professor of anaesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

